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Genome-scale CRISPR/Cas9 screen 
determines factors modulating 
sensitivity to ProTide NUC-1031
Awa Sarr1,2, Jennifer Bré1, In Hwa Um1, Tsz Huen Chan1, Peter Mullen1, David J. Harrison  1 & 
Paul A. Reynolds  1,2
Gemcitabine is a fluoropyrimidine analogue that is used as a mainstay of chemotherapy treatment for 
pancreatic and ovarian cancers, amongst others. Despite its widespread use, gemcitabine achieves 
responses in less than 10% of patients with metastatic pancreatic cancer and has a very limited impact 
on overall survival due to intrinsic and acquired resistance. NUC-1031 (Acelarin), a phosphoramidate 
transformation of gemcitabine, was the first anti-cancer ProTide to enter the clinic. We find it displays 
important in vitro cytotoxicity differences to gemcitabine, and a genome-wide CRISPR/Cas9 genetic 
screening approach identified only the pyrimidine metabolism pathway as modifying cancer cell 
sensitivity to NUC-1031. Low deoxycytidine kinase expression in tumour biopsies from patients treated 
with gemcitabine, assessed by immunostaining and image analysis, correlates with a poor prognosis, 
but there is no such correlation in tumour biopsies from a Phase I cohort treated with NUC-1031.
NUC-1031 (Acelarin), a phosphoramidate transformation of gemcitabine, is the first anti-cancer ProTide to enter 
the clinic1. Analogues of cytidine are the backbone of many therapeutic regimens in oncology. Historically, Ara-C 
(Cytarabine) and more recently, gemcitabine2, are first-line chemotherapy agents used in patients with pancreatic 
cancer3 and in combination treatments for ovarian, breast, biliary tract, lung, and bladder cancers4,5. Gemcitabine 
acts as a cytotoxic agent primarily by blocking DNA synthesis in cancer cells6–8. It is imported into cells through 
membrane transporters, including human Equilibrative Nucleotide Transporter 1 (hENT1), decreased expression 
of which in pancreatic cancer may be associated with poor overall survival9. Once inside the cell, gemcitabine 
requires phosphorylation to difluorodeoxycytidine monophosphate (dFdCMP) by deoxycytidine kinase (DCK), 
which represents the rate-limiting step for further phosphorylation to the active diphosphate (dFdCDP) and 
triphosphate (dFdCTP) metabolites2. Of these, dFdCTP is the more active and incorporates into DNA to inhibit 
its synthesis. Subsequent failure of DNA repair triggers apoptosis and inhibits tumour growth10,11. dFdCDP inac-
tivates ribonucleotide reductase, depleting the deoxyribonucleotide pools necessary for DNA synthesis, potenti-
ating the effects of dFdCTP12,13. Gemcitabine is also rapidly catabolized by cytidine deaminase (CDA) generating 
difluorodeoxyuridine (dFdU)14.
Despite its widespread use, gemcitabine achieves responses in less than 10% of patients with metastatic pan-
creatic cancer and has very limited impact on overall survival15. Many cancers have an innate resistance to gem-
citabine or, once exposed to gemcitabine, develop resistance, often within weeks of treatment initiation, markedly 
limiting its efficacy and clinical benefit8,16. Three key cancer cell resistance mechanisms have been associated with 
a poor survival prognosis for gemcitabine: transport, activation, and breakdown. Cells deficient in the nucleoside 
transporter hENT1 are highly resistant to gemcitabine17 and patients with pancreatic cancer who express low or 
undetectable levels of hENT1 have significantly lower median survival times than those with detectable levels18. 
Deficiency of the activating enzyme DCK led to acquired gemcitabine resistance in a human ovarian carcinoma 
cell line exposed to increasing levels of gemcitabine in vitro19 and patients with pancreatic cancer who express low 
levels of DCK have significantly poorer overall survival than those with high levels20. Finally, increased levels of 
the catabolising enzyme CDA have been associated with reduced median survival times in gemcitabine-treated 
patients with pancreatic cancer21.
The ProTide drug NUC-1031 is comprised of a pre-activated nucleotide analogue (gemcitabine monophos-
phate) and a protective phosphoramidate moiety, which is a specific combination of aryl, ester, and amino 
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acid groupings. Pre-clinical data show the increased lipophilicity of NUC-1031 enables it to circumvent 
hENT1-mediated transmembrane transport and, once inside the cell, the phosphoramidate protective group is 
cleaved off by esterases, releasing dFdCMP which is then rapidly converted to dFdCDP and dFdCTP, bypassing 
the rate-limiting step of phosphorylation by DCK. Furthermore, NUC-1031 avoids CDA-mediated catabolism, 
thus preventing dFdU accumulation22–24. Both nucleotide synthesis and degradation are important in maintain-
ing the dNTP pool and substrate cycling by 5ʹ‐nucleotidases and nucleoside kinases represent points of control25.
Genome-scale genetic knockdown screens have been successfully used to identify genes involved in drug 
resistance/sensitivity for a variety of chemotherapeutic agents26 and we employed this approach to screen for can-
didate genes mediating cancer cell sensitivity to NUC-1031. Surprisingly, the only pathway consistently selected 
was pyrimidine metabolism; specifically, multiple sgRNAs targeting two genes, DCK and deoxycytidine triphos-
phate pyrophosphate 1 (DCTPP1), involved in the maintenance of the dCMP/dCTP pool. In contrast, there were 
no consistent hits selected from the gemcitabine screen. We show that, although similar in structure, NUC-1031 
displays important in vitro cytotoxicity differences to gemcitabine. While we find low DCK expression in tumour 
biopsies from patients treated with gemcitabine, assessed by immunostaining and image analysis, correlates with 
a poor prognosis, we find no such correlation in tumour biopsies from a Phase I cohort treated with NUC-1031. 
These data suggest that in contrast to gemcitabine, low DCK expression should not preclude patients from con-
sideration for NUC-1031 treatment and that DCK is not a predictive marker of clinical response to NUC-1031.
Results
Exogenous dCyd confers complete resistance to gemcitabine while sensitivity to NUC-1031 is 
retained. In order to investigate the effect of NUC-1031 and gemcitabine on dCMP/dCTP pool regulation, 
cytotoxicity assays for NUC-1031 and gemcitabine were carried out on MiaPaCa2 pancreatic cancer cells and 
A2780 ovarian cancer cells. In the presence of deoxycytidine (dCyd) to competitively inhibit DCK, MiaPaCa2 and 
A2780 cells (Fig. 1A,B) were completely resistant to gemcitabine, confirming the requirement of DCK for gem-
citabine activation. By contrast, at equal concentrations of dCyd, NUC-1031 retained its cytotoxicity (Fig. 1C,D), 
albeit showing a modest decrease (30–35% reduction at equimolar doses). While dCyd does partially impair 
NUC-1031 activity, the effect was much less than the complete inhibition seen with gemcitabine. Pre-treatment of 
cells with dCyd before the addition of NUC-1031 also showed similar results (Fig. S1). These data are consistent 
with the phosphorylated status of NUC-1031, compared to gemcitabine.
To further elucidate these differences, cell cycle analysis was performed on A2780 cells treated at the IC50 dose 
of NUC-1031 or gemcitabine for 2 h, followed by media washout. At 24 h after washout, more A2780 cells were 
in S phase after treatment with gemcitabine (62.1%) or NUC-1031 (57.85%) compared to DMSO-treated control 
(36.85%) (Fig. S2). However, at 48 h after washout, more A2780 cells were arrested in S phase after treatment with 
NUC-1031 (50.65%) than after treatment with gemcitabine (40.05%) or DMSO (36.55%) (Fig. S2). At 72 h after 
washout, more A2780 cells were in G2/M phase after treatment with NUC-1031 (18.95%) than after treatment 
with gemcitabine (12.6%) or DMSO (8.13%) (Fig. S2). Taken together, these data suggest that NUC-1031 and 
gemcitabine display important in vitro cytotoxicity differences and that the effects of NUC-1031 persist for longer 
in vitro, compared to gemcitabine.
Figure 1. Exogenous dCyd negates efficacy of gemcitabine but not NUC-1031. (A,B) Dose-response curves for 
MiaPaCa2 or A2780 cells 4d after treatment with gemcitabine or (C,D) NUC-1031 and simultaneous addition 
of either DMSO, 50 µM or 100 µM of deoxycytidine (dCyd). Values represent mean +/− SEM (n = 6). A2780 vs 
A2780 + 50 µM dCyd vs A2780 + 100 µM dCyd: p = 0.0022; Mann-Whitney test).
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Genome-Scale CRISPR/Cas9 screen implicates pyrimidine metabolism in NUC-1031 sensi-
tivity. To identify genes involved in modulating resistance/sensitivity to NUC-1031 or gemcitabine, the 
GeCKOv2 genome-scale CRISPR/Cas9 knockdown library27,28 was used in pancreatic MiaPaCa2 cells and sgRNA 
distribution compared by next generation sequencing after 14d and 21d of drug treatment (Fig. 2A; Fig. S3). 
Exposure to either NUC-1031 or gemcitabine resulted in retarded population growth of transduced MiaPaCa2 
cells (Fig. 2B), therefore enabling the enrichment of a small group of cells that were rendered more drug-resistant 
by Cas9:sgRNA-mediated modification. After 14d and 21d of NUC-1031 treatment, the sgRNA distribution 
was significantly different when compared to DMSO (vehicle)-treated cells, particularly after 21d, as well as an 
increased variability, illustrated by a larger interquartile range, indicating the selection of specific sgRNAs in 
response to the treatment (Fig. 2C; p < 2.2 × 10−16, Mann-Whitney/Wilcoxon rank sum test). Interestingly, gem-
citabine treatment induced a smaller but statistically significantly different sgRNA distribution, compared to 
DMSO-treated cells (Fig. 2C; p = 0.001117 at d14, p < 2.2 × 10−16 at d21; Mann-Whitney/Wilcoxon rank sum 
test). For a subset of genes, there was enrichment of multiple sgRNAs that target each gene after 14d and 21d 
of NUC-1031 treatment (Fig. 2D), suggesting that loss of these particular genes contributes to increased NUC-
1031 resistance. In contrast, there were no consistent hits from the gemcitabine screen (Fig. 2E, Table S1). The 
MAGeCK algorithm29 was used to rank screening hits by the consistent enrichment among multiple sgRNAs 
targeting the same gene (Fig. 2F,G). The highest-ranking genes included the previously reported gemcitabine 
resistance factor DCK30 and also several other genes, including DCTPP1, implicated in modulating intracellular 
dCTP31 (Table 1). These hits were also identified through a second independent library transduction (Fig. S4, 
Table S1).
Validation of candidate genes. Top-ranking genes from the GeCKOv2 screen were validated individ-
ually using independent sgRNAs cloned into pLentiCRISPRv2 and transduced into MiaPaCa2 cells in order to 
generate distinct knockdown cell lines for each gene. For DCK, knockdown efficiency was assessed by Western 
blot and DCK expression was found reduced by more than 70% in the MiaPaCa2 knockdown cell lines com-
pared to MiaPaCa2-sgScr cells (Fig. 3A). Interestingly, the sgRNAs conferred a 4.5 to 7-fold increased resistance 
to NUC-1031 in MiaPaCa2-sgDCK cells, compared to MiaPaCa2-sgScr cells (Fig. 3B). However, at NUC-1031 
concentrations of 250 nM, there was approximately 34% death (range of 21–47% for the 3 sgRNAs), compared 
to MiaPaCa2-sgDCK cells treated with gemcitabine that survived and were completely resistant to 250 nM gem-
citabine (Fig. 3B). Likewise, ovarian A2780-sgDCK cells treated with gemcitabine were completely resistant 
to 500 nM gemcitabine, whereas A2780-sgDCK cells treated with NUC-1031 were 2-fold more resistant (IC50 
sgDCK 242 nM vs IC50 sgScr 103 nM; p = 0.0022), compared to A2780-sgScr cells (Fig. 3B).
For DCTPP1, knockdown efficiency was assessed by Western blot analysis and DCTPP1 expression was 
found to be reduced by more than 90% in the MiaPaCa2 knockdown cell lines compared to MiaPaCa2-sgScr 
cells (Fig. 4A). Interestingly, the DCTPP1 sgRNAs conferred a 1.5-fold decreased sensitivity to NUC-1031 in 
MiaPaCa2-sgDCTPP1 cells, compared to MiaPaCa2-sgScr cells, indicating a small but consistent decrease in 
MiaPaCa2 cells sensitivity to NUC-1031 in the absence of DCTPP1 (Fig. 4B). On the contrary, no change in 
sensitivity was detected in MiaPaCa2-sgDCTPP1 cells compared to MiaPaCa2-sgScr cells in response to gem-
citabine treatment (Fig. 4B). No change in sensitivity was detected for NUC-1031 or gemcitabine in pancreatic 
PSN1-sgDCTPP1 cells, compared to PSN1-sgScr cells (Fig. 4B). These data suggest that the modulatory effect of 
DCTPP1 on NUC-1031 sensitivity is specific to MiaPaCa2 cells.
Simultaneous knockdown of DCTPP1 and DCK shows no synergy. Since both DCK and DCTPP1 
are involved in pyrimidine metabolism and maintenance of the dCMP pool, simultaneous inactivation of DCK 
and DCTPP1 was performed to assess for any synergistic effects, compared with individual knockdown. One guide 
RNA targeting DCK (sgDCK) and one targeting DCTPP1 (sgDCTPP1) or two non-targeting guide RNAs (sgScr), 
were cloned into pX333. Control (pX333 sgScr-sgScr) and double knockdown (pX333 sgDCK-sgDCTPP1) plas-
mids were introduced independently into MiaPaCa2 and A2780 cells by nucleofection. DCK protein expression 
was reduced by approximately 86% and DCTPP1 by approximately 72% in MiaPaCa2-sgDCK-sgDCTPP1 cells 
(Fig. 5A). MiaPaCa2-sgDCK-sgDCTPP1 cells displayed a 5-fold decreased sensitivity to NUC-1031, compared 
to MiaPaCa2-sgScr-sgScr cells, while MiaPaCa2-sgDCK-sgDCTPP1 cells were completely resistant to gemcit-
abine (Fig. 5B). Similar results were observed in A2780 cells with decrease of protein expression by 85% and 90% 
for DCK and DCTPP1, respectively. A2780-sgDCK-sgDCTPP1 cells displayed a 3-fold decreased sensitivity to 
NUC-1031, compared to A2780-sgScr-sgScr cells, while A2780-sgDCK-sgDCTPP1 cells were completely resist-
ant to gemcitabine (Fig. 5B). These data suggest there is no synergistic effect on NUC-1031 sensitivity by simulta-
neously reducing both DCK and DCTPP1 expression.
DCK expression is not predictive in patients treated with NUC-1031. In order to assess the clinical 
relevance of DCK and DCTPP1 expression, cancer biopsy tissues from either pancreatic cancer patients who 
received gemcitabine/did not receive chemotherapy or from patients from a pan-cancer Phase I cohort treated 
with NUC-1031 were immunostained using antibodies to DCK and DCTPP1, and scanned images obtained from 
Zeiss AxioScan were quantified using QuPath32. After review by a pathologist (DJH), 60 pancreatic cancer tissue 
microarray (TMA) cores were identified as containing tumours, and these had associated survival data. DCTPP1 
was expressed in 50 out of 60 pancreatic cancer cores, mainly in tumour cells that displayed mostly nuclear locali-
zation but also in cells in the tumour microenvironment, where DCTPP1 was localized in both the cytoplasm and 
nucleus. DCK was expressed in 55 out of 60 pancreatic cancer cores, in the cytoplasm and strongly in the nucleus, 
not only in tumour cells, but also in stromal and immune cells in the tumour microenvironment (Fig. 6A). To 
determine whether DCTPP1 and DCK expression levels were associated with patient outcome, Kaplan-Meier 
(KM) analyses were performed on histoscores using TMA navigator (www.tmanavigator.org33). KM analysis 
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Figure 2. Genome-Scale CRISPR/Cas9 Screen Implicates DCK and DCTPP1 in NUC-1031 sensitivity. 
(A) Experimental design of the GECKOv2 screen for gemcitabine and NUC-1031 resistance, performed in 
MiaPaCa2 cells, in 2 biological replicates. (B) MiaPaCa2 cell number at d0, d14 and d21 after treatment with 
either dimethyl sulfoxide (DMSO) as control, gemcitabine or NUC-1031. (C) Heat map of sgRNA abundance 
comparing biological replicates and treatment conditions. (D,E) Distribution of sgRNA reads frequency 
before treatment (Baseline), in DMSO (Control), NUC-1031 or gemcitabine treated cells after d14 and d21 
of exposure. The box extends from the first to the third quartile with the whiskers denoting 1.5 times the 
interquartile range and show an increased variability of sgRNA frequency in cells treated with NUC-1031 
compared DMSO treated cells. (F) Scatterplot of sgRNA read counts in NUC-1031 treated cells compared to 
control (DMSO) cells showing enrichment of DCK and DCTPP1 sgRNAs after 14d exposure. (G) Identification 
of candidate genes, targeted by enriched sgRNAs, in NUC-1031 treated cells compared to control cells, using 
MAGeCK p-value analysis.
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showed that there was no significant difference in survival (FDR corrected p-value = 0.3595) between those 
patients with low DCTPP1 expression (histoscores 0 to 15.68), those with medium DCTPP1 expression (his-
toscores 15.83 to 51.98) and those with high DCTPP1 expression (histoscores 52.31 to 149.38) (Fig. 6B). However, 
as expected from previous studies, KM analysis showed that patients with low DCK expression (histoscores 0 to 
MAGeCK 
rank
gemcitabine NUC-1031
Negative selection Positive selection Negative selection Positive selection
Day 14 Day 21 Day 14 Day 21 Day 14 Day 21 Day 14 Day 21
1 CSF3R NAA10 PP1R32 TSC2 TSC2 hsa-mir-555 TMEM165 TMEM165
2 LRRC24 POLR2D hsa-mir-4711 CRYGC ZBTB46 TSC2 DCK DCK
3 POLB PELO NCOA3 ATRNL1 TSC1 DMPK PYCR2 NTC_0397
4 MBLAC2 RPL14 CENPE SH3BP4 ZNF281 PCOLCE DCTPP1 SIRPD
5 NPBWR1 HPS5 UGGT2 hsa-mir-6727 COL4A1 OR10A5 SYNCRIP TSPAN12
6 COG7 HM13 ARL1 MAP4K5 DDIT4 RUFY1 NTC_0731 HCN3
7 CTTNBP2 WDR43 hsa-mir-548h-5 hsa-mir-1254-2 OR51E2 hsa-mir-185 RASSF7 POMP
8 TNFRSF1A COX5A UBXN2A NTC_0555 PHTF1 OR1M1 NACC2 NTC_0203
9 WWP2 XRCC5 NADK2 hsa-mir-1265 ERBB2IP CCDC42B NTC_0040 NTC_0045
10 ATP6V1B1 KIAA1239 CLEC19A CDH29 LHPP KCNA3 COQ4 DDO
Table 1. Top ranked genes from MAGeCK analysis. Genes ranked by MAGeCK by either negative selection or 
positive selection in gemcitabine or NUC-1031 treated cells after d14 and d21 of exposure.
Figure 3. DCK mediates NUC-1031 sensitivity in pancreatic and ovarian cancer cells. (A) DCK protein 
expression analyzed by Western blot in MiaPaCa2 and A2780 cells transduced with independent sgRNAs 
targeting DCK (sgDCK) or a non-targeting scrambled control sgRNA (sgScr). (B) Dose-response curves for 
MiaPaCa2 and A2780 cells transduced with individual sgRNAs targeting DCK or a non-targeting scrambled 
control sgRNA (sgScr) and treated with NUC-1031 or gemcitabine (n = 6, +/−SEM. MiaPaCa2 sgScr vs 
MiaPaCa2 sgDCK: p = 0.0022, A2780 sgScr vs A2780 sgDCK: p = 0.0022 for NUC-1031 and p = 0.0043 for 
gemcitabine; Mann-Whitney test).
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30.19), had a significantly shorter survival (FDR corrected p-value = 8.63 × 10−6) than those with medium DCK 
expression (histoscores 30.77 to 57.64) or high DCK expression (histoscores 58.33 to 96.88) (Fig. 6B).
From the NUC-1031 treated Phase I cohort, 39 biopsies from 37 patients with clinical follow-up were ana-
lyzed1. All patients had rapidly progressing disease on study entry and had exhausted all other treatment options. 
Of these, two patients achieved a partial response (unconfirmed) to NUC-1031 according to RECIST 1.1 criteria, 
thirteen patients achieved stable disease for six months or more and twenty-two patients achieved stable disease 
for less than six months, or progressive disease developed within that time. Patients with progressive or stable 
disease for less than 6 months showed no significant difference in DCK or DCTPP1 expression by histoscore, 
compared to those who had stable disease for more than 6 months or had a partial response (Fig. 7A, Fig. S5). 
Interestingly, a lung cancer from a partial responder, who had not been previously treated with gemcitabine and 
survived for 10 months while receiving NUC-1031, displayed high DCK expression. A pancreatic cancer from a 
second patient who had relapsed on prior gemcitabine treatment but achieved a 30% reduction in tumour vol-
ume (partial response) within 3 cycles of NUC-1031 treatment, displayed low DCK expression (Fig. 7B). These 
data suggest that in tumours from NUC-1031 treated patients, DCK expression does not strongly correlate with 
disease progression.
Discussion
Despite its widespread use as a mainstay of chemotherapy in patients with pancreatic, ovarian, lung, breast and 
biliary tract cancers, amongst others, the fluoropyrimidine gemcitabine achieves responses in less than 10% of 
patients with metastatic pancreatic cancer and has a very limited impact on overall survival due to intrinsic 
and acquired resistance. NUC-1031, a phosphoramidate transformation of gemcitabine, was the first anti-cancer 
Figure 4. DCTPP1 mediates NUC-1031 sensitivity in pancreatic cancer cells. (A) DCTPP1 protein expression 
analyzed by Western blot in MiaPaCa2 and PSN1 cells transduced with independent sgRNAs targeting DCTPP1 
(sgDCTPP1) or a non-targeting scrambled control sgRNA (sgScr). (B) Dose-response curves for MiaPaCa2 and 
PSN1 cells transduced with individual sgRNAs targeting DCTPP1 or a non-targeting scrambled control sgRNA 
(sgScr) and treated NUC-1031 or gemcitabine (n = 6, +/−SEM. For NUC-1031: MiaPaCa2 sgScr vs MiaPaCa2 
sgDCTPP1a: p = 0.0022; MiaPaCa2 sgScr vs MiaPaCa2 sgDCTPP1b: p = 0.0087; MiaPaCa2 sgScr vs MiaPaCa2 
sgDCTPP1c: p = 0.0152;, for gemcitabine: MiaPaCa2 sgScr vs MiaPaCa2 sgDCTPP1a: p = 0.0649; MiaPaCa2 
sgScr vs MiaPaCa2 sgDCTPP1b: p = 0.3939; MiaPaCa2 sgScr vs MiaPaCa2 sgDCTPP1c: p = 0.8182 and PSN1 
sgScr vs PSN1 sgDCTPP1a: p = 0.1797; PSN1 sgScr vs PSN1 sgDCTPP1b: p = 0.8182; PSN1 sgScr vs PSN1 
sgDCTPP1c: p = 0.3939; Mann-Whitney test).
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ProTide to enter the clinic. We find that: (1) NUC-1031 and gemcitabine display important in vitro cytotoxicity 
differences; (2) the only pathway consistently selected with NUC-1031 in our CRISPR/Cas9 screen was pyrimi-
dine metabolism, while there were no hits consistently selected with gemcitabine under our selection conditions; 
(3) low DCK expression in tumour biopsies from patients treated with gemcitabine correlates with a poor prog-
nosis, but there is no such correlation in tumour biopsies from a Phase I cohort treated with NUC-1031.
Although similar in structure to gemcitabine24, these data demonstrate that ProTide chemistry does alter cyto-
toxicity and the effects of NUC-1031 are prolonged over time. These properties allowed for on-target, long-term 
in vitro selection with NUC-1031 in our genetic screening approach that consistently selected pyrimidine metab-
olism through the identification of DCK and DCTPP1, both of which regulate the dCMP/dCTP pool. The screen-
ing process was sufficiently sensitive to uncover DCTPP1 displaying a 1.5-fold change in sensitivity to NUC-1031. 
No major resistance factors to NUC-1031 were identified in this screen, since no other genes, except DCK, val-
idated with more than a 2-fold change and the effects of DCK loss on NUC-1031 resistance were very modest 
compared to those of gemcitabine, with a minimal loss of NUC-1031 sensitivity in cancer cell lines.
Contrary to NUC-1031, no consistent candidates were selected from the gemcitabine screen. This may be 
explained by the pleiotropic effects of gemcitabine and the long exposure time to gemcitabine in our study, 
which generates off-target toxicity especially through the production of dFdU metabolites. There are multiple 
resistance-associated genes for gemcitabine, including DCK, hENT1, CDA, RRM1 and RRM2 that all converge 
on a common mechanism17,34. Previously reported gemcitabine genetic screens used shorter exposure times, 
when compared to our study and none of these screens selected these known resistance factors35–37. Since DCK, 
hENT1, CDA, RRM1 and RRM2 were not selected in our gemcitabine screen, although they were present in the 
Figure 5. DCK and DCTPP1 simultaneous knockdown induced no synergistic effect in pancreatic and ovarian 
cancer cells to NUC-1031. (A) DCK and DCTPP1 protein expression analyzed by Western blot in MiaPaCa2 
and A2780 cells transfected with a pX333 plasmid containing sgRNA sequences targeting DCK (sgDCK) and 
DCTPP1 (sgDCTPP1) or a non-targeting scrambled control sgRNA (sgScr). (B) Dose response curves for 
MiaPaCa2 and A2780 sgDCK-sgDCTPP1 cells and sgScr-sgScr cells (control), 4d after treatment with NUC-
1031 or gemcitabine (n = 6, +/−SEM. MiaPaCa2 sgScr-sgScr vs MiaPaCa2 sgDCKe-sgDCTPP1a: p = 0.0022, 
A2780 sgScr vs A2780 sgDCK-sgDCTPP1: p = 0.0022; Mann-Whitney test).
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library representation (rank position DCK >1951, hENT1 >1999, CDA >1241, RRM1 >1541, RRM2 >593, 
respectively), we hypothesize that there may have been adaptation responses to the gemcitabine selection pressure 
on the CRISPR/Cas9 library. Therefore, caution should be used when performing CRISPR/Cas9 screens, since 
Figure 6. DCK expression is associated with outcome in gemcitabine-treated patients. (A) DCTPP1 expression 
in one tissue core before (left panel) and after (right panel) QuPath analysis based on staining intensity in 
tumour cells. A histoscore of 115.739 was calculated based on the proportion of positive cells and their staining 
intensity. DCK expression in a second tissue core before (left panel) and after (right panel) QuPath analysis 
based on staining intensity in tumour cells. A histoscore of 69.4313 was calculated based on the proportion of 
positive cells and their staining intensity. (B) KM survival curves for DCTPP1 and DCK expression generated 
using TMA Navigator. All of the tissue cores were divided in three groups according to their histoscore. Each 
group was composed of 20 samples presenting histoscores in the indicated ranges. Survival of patients is 
presented in months.
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Figure 7. DCK expression in archival tissue does not correlate with outcome in patients treated with NUC-
1031. (A) Nucleus and cytoplasm DCK histoscores in tissue from patients who achieved stable disease for less 
than six months, or progressive disease developed within that time (group 1, n = 22), or who achieved stable 
disease for six months or more (group 2, n = 17). Tissues were immunostained for DCK and scanned images 
were quantified using QuPath and histoscores compared between groups (DCK nucleus p-value = 0.2102; DCK 
cytoplasm p-value = 0.1461; Mann-Whitney test). (B) Lung cancer from a partial responder, who had not been 
previously treated with gemcitabine and survived for 10 months while receiving NUC-1031, displayed high 
DCK expression. QuPath segmentation of tumour (red) and stroma (green) (left panel) or unsegmented image 
(right panel). Blue arrow, DCK nuclear expression. Red arrow, DCK cytoplasmic expression. (C) Pancreatic 
cancer from a patient who had relapsed on prior gemcitabine treatment but achieved a 30% reduction in 
tumour volume (partial response) within 3 cycles of NUC-1031 treatment, displayed low DCK expression. 
QuPath segmentation of tumour (red) and stroma (green) (left panel) or unsegmented image (right panel). Blue 
arrow, DCK negative cancer cell. Red arrow, DCK negative immune cell.
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this methodology may not uncover very strongly selected genes and may be dependent on factors such as in vitro 
drug metabolism effects.
We have used QuPath32 quantitative image analysis of DCK and DCTPP1 expression in tumour tissue biopsies 
from a Phase I patient cohort treated with NUC-1031 (ref. 1), involving the fast and interactive training of object 
classifiers using machine learning techniques. The analysis of 39 biopsies, from a range of different tumours, did 
not show a correlation between DCK and DCTPP1 expression and efficacy of NUC-1031. Although the number 
of patients is small, the data suggest that NUC-1031 achieved clinical activity even in patients with low DCK 
expressing tumours. Further clinical studies are warranted to assess the long-term efficacy of NUC-1031 treat-
ment in patients and monitoring dCMP/dCTP levels in NUC-1031 treated tumours may be of benefit. In con-
clusion, these experiments support the notion that NUC-1031 overcomes the cancer cell resistance mechanisms 
that limit the clinical utility of gemcitabine. Importantly, patients who had previously relapsed on gemcitabine 
treatment show clinical responses to NUC-1031, further confirming the potential for NUC-1031 to represent a 
more effective treatment option for these patients.
Materials and Methods
Cell culture and reagents. MiaPaCa2 and HEK293T cell lines were cultured in Dulbecco’s modified Eagle 
medium (DMEM) supplemented with 10% (v/v) Fetal bovine serum and 1% (v/v) Penicillin/Streptomycin. 
A2780 and PSN1 cell lines were cultured in RPMI 1640 supplemented with 10% (v/v) Fetal bovine serum and 
1% (v/v) Penicillin/Streptomycin. Cells were routinely tested negative for Mycoplasma using the Minerva Biolabs 
‘Venor GeM One Step’ PCR kit.
Human GeCKOv2 CRISPR knockout pooled library was a gift from Feng Zhang (Addgene #1000000048). 
Pooled lentiCRISPRv2 expression vectors containing GeCKOv2 library were provided as two half-libraries A 
and B, at a concentration of 50 ng/µl. plentiCRISPRv2 was a gift from Feng Zhang (Addgene #52961) and pX333 
was a gift from Andrea Ventura (Addgene #64073). Gemcitabine (Sigma-Aldrich, UK) and NUC-1031 (provided 
by NuCana plc), were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, UK) at a stock concentration 
of 10 mM. 2′deoxycytidine (Sigma-Aldrich, UK) was dissolved in DMSO at a stock concentration of 100 mM. 
Nucleofection (Amaxa) was performed on MiaPaCa2 and A2780 cells using standard methods to introduce 
pX333.
Cytotoxicity assays. MiaPaCa2 and PSN1 cells were seeded in 96-well plates at a density of 500 cells per 
well. After 48 h, cells were incubated with culture media containing either 0.1% (v/v) DMSO or increasing con-
centrations of drug (gemcitabine or NUC-1031) from 5 nM to 250 nM in six experimental replicates. Cells treated 
with gemcitabine were washed out after 24 h and incubated with fresh media. A2780 cells were seeded in 96-well 
plates at a density of 750 cells per well. After 48 h, cells were incubated with culture media containing either 0.1% 
(v/v) DMSO or increasing concentrations of drug (gemcitabine or NUC-1031) from 5 nM to 500 nM in six exper-
imental replicates. Cells were washed out after 2 h and incubated with fresh media. The number of drug-treated 
cells at d4 post-treatment was assessed by Celigo cytometer (Nexcelom Bioscience) for MiaPaCa2 and PSN1 cells 
or Sulforodamine B (SRB) assay for A2780 cells and normalized to the count of DMSO-treated cells (control). Cell 
numbers obtained from Celigo or SRB analysis, were used to generate dose response curves and to calculate the 
concentration to get 50% of drug effect (IC50) for gemcitabine and NUC-1031, using Graphpad Prism software.
Flow cytometry. 5 × 105 A2780 cells were plated in 6 cm dishes and left to grow for 48 h. Cells were treated 
with IC50 of either NUC-1031 or gemcitabine or culture media containing 0.1% (v/v) DMSO for 2 h. After incu-
bation with BrdU (10 μM) for 30 mins prior to being collected, cells were trypsinized and centrifuged at 1200 rpm 
for 5 min, washed with PBS and centrifuged again before being re-suspended in 1 mL of ice-cold 70% ethanol 
and stored at 4 °C until staining for analysis on the flow cytometer. Cells were digested with pepsin (0.4 mg/mL 
in 100 mM HCl – Sigma P6887) for 45 min at 37 °C after which DNA was denatured with 2N HCL/0.5% Triton 
X-100 for 30 min at RT and then neutralized with 0.1M sodium tetraborate pH8.5. DNA staining was performed 
using an anti-BrdU antibody (Beckton Dickinson, clone B44) at a 1:100 dilution in PBS/0.5% BSA/0.5% Tween20 
and anti-mouse FITC (Alexa Fluor 488, Invitrogen A1101). Samples were incubated with RNAse A (Qiagen 
103130) and propidium iodide. They were run on a BD FACSJazzTM and data analysis was performed using 
FlowJo software v10.
Lentivirus production. Both half-libraries (A and B) were used and viral particles produced independently 
from A and B before being combined and used to infect recipient cells. 4 × 106 HEK293T cells were plated for 
each 10 cm dish and co-transfected the next day with 4 µg library A or B plasmids (lentiCRISPRv2), 2 µg pVSVg 
and 3 µg psPAX2 lentiviral packaging plasmids, using 27 µl of Trans-iT LT1 reagent (Mirus). Viral supernatant 
was collected 48 h and 72 h after transfection. Viral collections at 48 h and 72 h were pooled together, passed 
through a 0.45 µm filter in the presence of 8 µg/ml polybrene (Sigma-Aldrich) and then used to infect recipient 
cells. A total of 2 × 108 MiaPaCa2 cells were infected with lentiviral particles containing GeCKOv2 library at a 
MOI of 0.3 (aiming for ~300X coverage per sgRNA). Transduced cells were then selected for 7d with 2 µg/ml 
puromycin (Sigma-Aldrich).
GeCKOv2 screen for gemcitabine and NUC-1031 resistance/sensitivity. 6 × 107 transduced cells 
were collected as a baseline for sgRNA distribution at the start of the screen. Remaining MiaPaCa2 cells were 
divided into three conditions with a minimum of 2.6 × 107 cells for each. They were either treated with DMSO as 
a control, 15 nM gemcitabine or 65 nM NUC-1031. Cells were maintained for four weeks and cell pellets consist-
ing of 6 × 107 cells were collected 14d and 21d after the start of the treatment. Genomic DNA was extracted from 
these cells using Blood and cell Midi kit (Qiagen) and sgRNA sequences isolated by PCR. A second PCR reaction 
was carried out on the resulting amplicons to add adapter sequences for the sequencing system and barcodes 
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to discriminate each sample after multiplex NGS27,28 (Table S2). Quantification and purity of the resulting PCR 
products were evaluated using QubiT fluorometer, qPCR using KAPA Library Quantification Kit for Illumina 
platforms and Agilent 2100 Bioanalyzer system. Barcoded sgRNAs were then sequenced using the Illumina HiSeq 
2500 system by Edinburgh Genomics, The University of Edinburgh.
Sequencing data analysis. Raw sequencing reads from NGS were demultiplexed then, 5′ Illumina adapter 
sequences were trimmed using Cutadapt 1.3. Trimmed reads were then aligned to the reference GeCKOv2 library 
using Bowtie 0.12.9. The number of reads uniquely mapped to each reference sgRNA sequence was calculated and 
read count per sgRNA was normalized as follows: (read count per reference sequence/total of uniquely aligned 
reads for all sgRNAs in sample) × 106. Graphic representations of sgRNA counts were generated using R Studio 
software. Read counts from each sample were then analyzed using the MAGeCK algorithm29 to rank and prior-
itize sgRNAs and genes affecting MiaPaCa2 cells sensitivity or resistance to gemcitabine and NUC-1031.
Western Blotting analysis. 1 × 106 cells were plated onto 10 cm petri dishes and left to grow for 48 h. 
Cells were washed with ice-cold PBS and lysed in a lysis buffer composed of: 10 mM Tris pH 8.0, 150 mM NaCl, 
1% sodium deoxycholate, 1% Nonidet P-40 (NP40), 1% Sodium dodecyl sulfate (SDS), 1 mM EDTA and sup-
plemented with 1X protease inhibitor (AMV Roche), phosphatase inhibitor cocktail 2 and 3 (Sigma-Aldrich), 
2 mM phenylmethylsulfonyl fluoride (PMSF) (SigmaAldrich). 200 µL of supplemented lysis buffer were added 
to each plate, then protein extracts were collected and quantified by Bicinchoninic Acid (BCA) assay using 
Pierce BCA protein assay kit (Thermo Scientific, UK). 30 µg of lysates were resolved by SDS Polyacrylamide Gel 
Electrophoresis, then transferred on a PVDF membrane. Immunoblotting was carried out at 4 °C overnight using 
the following antibodies: XTP3TPA/DCTPP1 (B-6) (Santa Cruz #sc-398501), DCK (Genetex #GTX102800), 
GAPDH (Sigma-Aldrich #G8795), β actin (Cell Signaling Technology #8H10D10). GAPDH and β actin were 
used as loading controls.
Immunohistochemistry and machine learning analysis. Tissue microarray (TMA) samples were 
obtained from a cohort of patients with pancreatic cancer (Table S3). Ethical approval was granted by Scotland 
A REC (10/S1402/33) for the generic use of pathology archive tissue for research. Whole section slides from a 
pan-cancer Phase I cohort were also obtained (Table S4) where all biopsies were taken prior to NUC-1031 treat-
ment1. Corresponding clinical data was also obtained from clinical records including tumour diagnosis, sex, 
and details on previous chemotherapy, and response if any to NUC-1031. Since ORR was not a primary focus, 
routine scans were conducted every 8 weeks. Patients did not receive confirmatory scans, i.e., 4 weeks after initial 
documentation of response, as per RECIST 1.1. All data was rendered patient non-identifiable prior to receipt. 
All methods were carried out in accordance with relevant guidelines and regulations and informed consent was 
obtained from all subjects. All experimental protocols were approved by University of St Andrews Teaching and 
Research Ethics Committee.
Slides were immersed three times in Xylene for 5 min and rehydrated in graded concentrations of alcohol 
(100, 100, 80 and 50%) for 2 min each and then rinsed in running water. Heat-induced antigen retrieval was per-
formed in boiling Citrate buffer (10 mM, pH 6.0) at 99 °C in an automatic pressure cooker for 5 min. Endogenous 
peroxide activity was blocked by incubation of the slides with 3% hydrogen peroxide, for 5 min followed by a 
5 min wash in 0.1% PBS-T. Serum-free block solution (DAKO, Agilent, UK) was added on the TMA for 10 min. 
DCTPP1 and DCK primary antibodies (XTP3TPA/DCTPP1 (B-6) (Santa Cruz #sc-398501), DCK (Genetex 
#GTX102800)), were diluted in DAKO diluent to 1:500 and 1:1500 respectively. EnVision HRP-conjugated 
anti-Mouse or anti-Rabbit secondary antibody were added to the appropriate TMA. DAB chromogen (DAKO, 
Agilent, UK) was added to each slide for 10 min. Tissues were dehydrated, cleared in Xylene and then mounted 
with DPX mounting medium (Sigma-Aldrich, UK) and left to dry overnight. Slides were scanned and imaged 
using a Leica SCN400 brightfield microscope. The analysis of stained tissues images was carried out using QuPath 
software. Four categories of staining intensity were then created using three different thresholds to classify cells 
according to their staining intensity: cells with an optical density (OD) below 0.2 were considered negative, OD 
between 0.2 and 0.4 were weakly positive (1+), between 0.4 and 0.6 were moderately positive (2+) and above 
0.6 were strongly positive (3+). QuPath was then trained to distinguish different tissue areas and cellular types 
within tissue cores (including non-neoplastic cells, tumour cells, immune cells, stroma, red blood cells, necrosis), 
by drawing around representative areas or cells and annotating them. The set parameters were then applied to 
analyze all tissue cores. Each tissue core was then controlled to ensure that only tumour cells were analysed, and 
all areas analysed outside tumour cells were removed. QuPath calculated histoscores of each case, based on the 
staining intensity within tumour cells and their proportion.
Statistical analysis. Statistical analysis of sgRNA count were performed using R studio software and 
MAGeCK program. All other statistical analyses were conducted using Graphpad Prism software. Mann Whitney 
U test was used when at least four replicates were available. P value < 0.05 was considered statistically significant.
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